【制药网 行业动态】在竞争激烈的医药市场中,企业架构调整是适应行业变化、提升竞争力的重要手段。据业内多方消息透露,自7月1日起,阿斯利康中国即将迎来新一轮架构调整,设立消化道肿瘤事业部(GIBU)与早期管线业务部(EarlyAssetsUnit)两大全新业务板块。这一举措,标志着阿斯利康在中国市场的战略布局再次升级,尤其在肿瘤领域的深耕愈发深入。此次新设立的消化道肿瘤事业部,将聚焦于胆道癌、肝癌、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.